ARTICLE | Company News
Collateral, Schering deal
August 20, 2001 7:00 AM UTC
CLTX received a $4 million payment from SHR triggered by the clinical advancement of CLTX's Generx and Genvascor adenoviral gene therapy technologies encoding human fibroblast factor-4 (FGF-4) (see ...